Symbols

Bioxcel Therapeutics Soars 18.8% on Phase III Trial Announcement

Generated by AI AgentAinvest Pre-Market Radar

Monday, Aug 18, 2025 4:26 am ET1min read

Aime Summary

- Bioxcel Therapeutics' stock surged 18.8% pre-market after announcing a phase III trial for BXCL501 to treat agitation in bipolar/schizophrenia.

- The upcoming release of SERENITY At-Home trial data this month boosted investor confidence in the company's mental health treatments.

- Positive results could lead to regulatory approvals and expanded market opportunities for the biotech firm.

On August 18, 2025, Bioxcel Therapeutics' stock surged by 18.8% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Bioxcel Therapeutics has recently made headlines with the announcement of a phase III trial evaluating the safety of a 120-mcg dose of BXCL501 for the acute treatment of agitation associated with bipolar disorders or schizophrenia. This trial is part of the company's ongoing efforts to develop innovative treatments for mental health conditions, which has been a key driver of investor interest.

The upcoming release of SERENITY At-Home trial data this month is another significant event that has contributed to the positive sentiment surrounding Bioxcel TherapeuticsBTAI--. The data is expected to provide further insights into the efficacy and safety of the company's treatments, potentially leading to regulatory approvals and expanded market opportunities.

Ainvest Pre-Market Radar

Get the scoop on pre-market movers and shakers in the US stock market.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

Add a public comment...

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue